INKON Life Technology Co Ltd
SZSE:300143
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6.75
10.99
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
INKON Life Technology Co Ltd
INKON Life Technology Co Ltd
Cost of Revenue
INKON Life Technology Co Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
INKON Life Technology Co Ltd
SZSE:300143
|
Cost of Revenue
-¥1.2B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-16%
|
|
|
H
|
Hygeia Healthcare Holdings Co Ltd
HKEX:6078
|
Cost of Revenue
-¥2.8B
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
N/A
|
|
|
A
|
Aier Eye Hospital Group Co Ltd
SZSE:300015
|
Cost of Revenue
-¥10.3B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-24%
|
|
|
X
|
XiAn International Medical Investment Co Ltd
SZSE:000516
|
Cost of Revenue
-¥4.5B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
-4%
|
|
|
H
|
Huaxia Eye Hospital Group Co Ltd
SZSE:301267
|
Cost of Revenue
-¥2B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Sanbo Hospital Management Group Ltd
SZSE:301293
|
Cost of Revenue
-¥1B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
INKON Life Technology Co Ltd
Glance View
INKON Life Technology Co., Ltd. engages in the research, development, production and sale of edible fungus. The company is headquartered in Qingdao, Shandong and currently employs 1,791 full-time employees. The company went IPO on 2011-04-22. Its medical services focus on cancer prevention, diagnosis, treatment and rehabilitation. The firm is also engaged in the research and development, manufacture and sales of medical equipment, as well as medical software development. Its medical equipment mainly include MASEP digital radiotherapy equipment, MASEP Gamma Knife and other large medical equipment. The firm distributes its products within domestic market and to overseas markets.
See Also
What is INKON Life Technology Co Ltd's Cost of Revenue?
Cost of Revenue
-1.2B
CNY
Based on the financial report for Sep 30, 2024, INKON Life Technology Co Ltd's Cost of Revenue amounts to -1.2B CNY.
What is INKON Life Technology Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-16%
Over the last year, the Cost of Revenue growth was -20%. The average annual Cost of Revenue growth rates for INKON Life Technology Co Ltd have been -20% over the past three years , -33% over the past five years , and -16% over the past ten years .
You don't have any saved screeners yet
